

Date: April 20, 2018

Time: 9:00 am – 11:00 am

Location: Portland State Office Building, 800 NE Oregon St., Portland, Oregon

Attendees:

OCC Attendees: Rachel Knox Subcommittee Members: Kevin Wilson, Janice Knox, Michael Rochlin, Ruben Halperin OMMP/OHA Staff: Carole Yann and Shannon McFadden Members of the Public as listed on the Sign in sheet:

Subgroups	Responsible Party
Training subgroup	Rachel Knox (lead)

Welcome and Introductions by the Oregon Cannabis Commission

Торіс	Key Discussion	Responsible
Description and	Our recommendations will cover areas of clinical training ranging from what	Rachel Knox
Directives	exists as a recommended requirement all the way to clinical master of	

The Oregon Cannabis Commission

Web Address: WWW.Healthoregon.org/cannabiscommission



recommendations to align these directives as we are creating our final recommendation or our first recommendation at the end of Q3 around



So specifically developing our training standards, our key component to
developing a robust and scalable Oregon Medical Marijuana Program and
you will see why.
SECTION 4.
(1) As soon as practicable after the effective date of this 2017 Act, the
Oregon Cannabis Commission shall determine:
(a) A possible framework for the future governance of the
Oregon Medical Marijuana
Program, including:
(A) Proper oversight and regulation of each of the following:
(i) Registry identification cardholders and designated primary caregivers,
as those terms are defined in ORS 475B.410;
(ii) Attending physicians, as defined in ORS 475B.410;
(iii) Marijuana grow sites, as defined in ORS 475B.410;
(iv) Marijuana processing sites, as defined in ORS 475B.410; and
(v) Medical marijuana dispensaries, as defined in ORS 475B.410;
(B) Necessary amendments to the laws of the state pertaining to cannabis, including any
necessary amendments to ORS 475B.010 to 475B.395 and 475B.400 to 475B.525; and
(C) The future role of the commission with respect to the possible framework.
(b) Steps that the state must take, whether administrative or legislative in nature, to
ensure that research on cannabis and cannabis-derived products is being conducted for public
purposes, including the advancement of:
(A) Public health policy and public safety policy;
(B) Agronomic and horticultural best practices; and
(C) Medical and pharmacopoeia best practices.
 (2) In determining the possible framework for the future governance of the Oregon

The Oregon Cannabis Commission

Web Address: WWW.Healthoregon.org/cannabiscommission



Training Subcommittee Meeting Minutes

Medical Marijuana Program under subsection (1)(a) of this section, the commission shall consider:(a) Potential factors that could prevent access to cannabis for medical use;(b) Potential laws and rules that will facilitate access to cannabis for medical use; and(c) The impact of federal laws, regulations and policies on the possible framework.(3) On or before December 15, 2017, the commission shall submit a reportin the manner prescribed by ORS 192.245to the interim committees of the Legislative Assembly related tohealth and judiciary on the findings anddeterminations made by the commission undersubsection (1) of this section. As part of the report, thecommission may make recommendations for legislation.(4) For purposes of making recommendations for legislation under subsection(3) of this section, after the effective dateof this 2017 Act and on or before December 15, 2017, thecommission may request an interim committee of the Legislative Assembly related to healthor judiciary to direct the Legislative Counsel to prepare legislative concepts for thecommission's consideration.	
So standardizing trainings for physicians training will improve oversight regulations for the physicians but we also want to talk about including the allayed help professionals also improving oversight for growers, processors and dispensaries workers. So right off the bat we'd be establishing some training guidelines and standardization in training will be hitting two of	



	those core competencies as what I will call them from here on out.	
	Standardize training will also unify the language that patients encounter and	
	the language that players in the industry as well as health care professionals	
	use to discuss cannabis care. And Lastly our training will wright a foundation	
	which will research public policy and public safety as well as R&D clinical	
	cannabis development and clinical care. Management can grow improve	
	and thrive in a more revamped Medical Marijuana Program and this is all to	
	provide better access to quality care for patients. So, this is why the	
	subcommittee was created and hopefully we will be able to fulfill several of	
	these directives.	
Review	Please see JUSTICE-#8644489-v2 Oregon Cannabis Commission public	Carole Yann
Subcommittee	meetings law presentation.	
Communication		
and Schedule	This Training Subcommittee will be scheduled monthly. Next meeting will be	
	held on May 18 th .	
	If any suggestions for agenda items from members, please email Shannon	
	McFadden at <u>Shannon.m.mcfadden@state.or.us</u>	



Training Subcommittee Meeting Minutes

Discussion:	Bringing training and clinical preparedness up to par.	Rachel Knox
Priority focus areas	Online resources as well as in person options for training and courses.	
	Language written in the policies that make physicians comfortable and that	
	their licenses are not going to be at risk, then you have a way to get more interested.	
	Really figure out a way to get the research that is out there into a way that is easily digestible because most people sort of assume this is all kind of	
	empirical and a lot of misconceptions about cannabis and opioids and things	
	like that. If people started to read this from people who are legitimate	
	researchers who are doing good work, who are putting together great trials	
	would go a long way to alleviating the fears in the medical community that	
	basically just extrapolating from stoners in the 70s who feel better.	
	We need those antidotal studies. Clinical research and collecting that data is	
	important but within that even they have a group of people and they are	
	looking at how whatever it is they are testing in each one of them and how	
	it contributes to the total picture. This is exactly what precision medicine is,	



how is it effecting that one individual and how we collect that data so that it
makes sense.
There is not precedent, we don't have a formal national sort of
authoritative agency for Cannabinoid Medicine just yet so there aren't any
clear guild lines on who to train or how to train. At Oregon in general and
Governor Brown want to be in the forefront of developing a pilot program
and that's essentially what we are doing here. So initially in September what
we are going to be developing a recommendation to what degree we think
training needs to be involved in this program. The next iteration will be
developing the types of programs that will need to be made so we can think
about how we would construct these programs but in that initial
recommendation in September we are really going to be way more higher
level, these are the training opportunities that need to be engaged and then
later we'll show you how and we can talk about the how to a degree in
these initial recommendations. This will be a arduous process to get training
programs set up for different tiers of professionals, like Dr. Janice Knox
mentioned, not everybody is going to need to be a specialist. Somebody will
need to be the specialist that providers can refer their patients to,



particularly industry folks who should be referring their patients to. How much should the average primary clinician know, how much should they be able to answer? Should every doctor be able to answer something and my answer would be yes. How do we ensure if someone went to separate doctors that they are giving similar advice? Previously for ORS 475B.400 no this language is written under ORS 475B.785	
(1) Patients and doctors have found marijuana to be an effective treatment for suffering caused by debilitating medical conditions and, therefore, marijuana must be treated like other medicines;	
(2) Oregonians suffering from debilitating medical conditions should be allowed to use marijuana without fear of civil or criminal penalties when a doctor advises that using marijuana may provide a medical benefit and when other reasonable restrictions are met regarding that use;	
(3) ORS <u>475B.785</u> (Findings) to <u>475B.949</u> (Authority to adopt rules for ORS <u>475B.785</u> to <u>475B.949</u>) are intended to allow Oregonians with debilitating medical conditions who may benefit from the medical use of marijuana to be able to freely discuss with doctors the possible risks and benefits associated with the medical use of marijuana and to have the benefit of professional medical advice; and	



Training Subcommittee Meeting Minutes

(4) ORS <u>475B.785 (Findings)</u> to <u>475B.949 (Authority to adopt rules for ORS 475B.785 to</u> <u>475B.949)</u> are intended to protect patients and doctors from criminal and civil penalties and are not intended to change current civil and criminal laws governing the use of marijuana for nonmedical purposes. [Formerly <u>475B.400</u>]
This is written to protect both patients and doctors from criminal and civil
penalty. So currently under statute physicians are protected in the state of
Oregon and that would go under doctors in Washington under their rules
and California. It is written in all these Medical Cannabis States that doctors
are protected from having conversations and writing authorizations so
maybe this needs to be clearer or under disseminated.
With the new direction on this issue surrounding Trump Administration
some doctors feel that they'd be hung out to dry at the federal level.
We need to get over this fear; there is no law against learning about this
information because we are scientists and are to deliver the safest
medicines. We need to lead this charge.
It must fit into a patient's diet and lifestyle and pharmaceutical
interventions and my interest is just sharing that information with other
colleagues and other professionals and hopefully this somehow overcomes



this divide between the budtenders. People come to me all the time and say
what do I do and I say well I want you on CBD and no I don't have it in the
office you have to go to a dispensary and then they are given something
else and occasionally they are given something with THC and they get
stoned and they are very uncomfortable and very unhappy and there's this
divide that we have to overcome and I just think there is some great
opportunity and I just come to it with excitement and enthusiasm and I
want to share that.
Training is the backbone it is the foundation of all the things that we are
going to be able to do and glean from cannabinoid medicine. But without
standardize training, without language that helps us all communicate, that
problem of giving a recommendation to a patient and going to a dispensary
and a budtender giving them something completely unattended is going to
have to go away but that's only going to happen if we only start tracking
information. So, on top of training we are going to have to think about, how
do we measure the impact of this training in clinical care management and
using technology that Dr. Janice Knox mentioned. How does this
information play back into product development so that the product that is



	
	on the shelf in dispensaries match what clinicians are suggesting to their
	patients? This program needs to work like an eco-system of which training is
	a very small piece but we must think about training in the context of all
	those things. So that this eco system becomes the Oregon Medical
	Marijuana Program that we can now take to other states and say this is a
	program that works, this is a program that improves our research and
	therefore improving clinical care which improves medical outcomes which
	gets all our patients off opiates etc. This is the exact lenses we need to be
	looking at this from. When we are talking about endocannobiology cannabis
	is just one little tool in an arsenal that really is natural medicine, integrated
	medicine, lifestyle medicine. And I think it is great that we all have an
	understanding because that training for that certified consultant in
	Cannabiology is going to have to include an integrated approach.
	The Oregon Commission can push forward the language that we use when
	we are talking about cannabis. When we are talking to patients about what
	they need, are we talking a language that is going to be understood here on
	the west coast, the east coast and overseas. We really need to push forward
	a common language where regardless of where you are, what physician,
l	



what caretaker you are you understand what that patient is saying. If that	
patient comes in and tells you I am taking some sativa you are going like	
what? So, what's that. We need to be able to talk specifics and for me that	
is taking it to a different level. That's talking using cannabis and	
cannabiology to a different level when we are talking specifics. This is the	
profile that I want you to go in that dispensary and look for. Don't ask for	
Indica or sativa or purple Kush. You ask for this chemical profile. You ask for	
this terpene profile. So, one of the things I hope that when pushing for an	
education we do that for not only health care providers but for processors	
and growers for labelers. All of them need to come to a common language	
that we all use and understand when anyone is talking to us about cannabis.	
Creating something that has the commission stamp on it, has the governors	
stamp on it legitimizes it as an educational tool for everyone in the world of	
health care for Oregon.	
Pleading ignorant as a physician is doing a disservice to that patient because	
if you don't give them the answer they will find it elsewhere which is a very	
dangerous and harmful route. If we are always thinking patient safety and	
provider accountability and protection I think we will be ok because	



information is really what we are trying coral here. Equipping a provider with the information so they are not harmful to a patient but to be more supportive and engage with that patient is what patient consumers really need. I am hoping this subcommittee and the commission in general can press cannabis education also into the realm of the inappropriate use to it or the side effects to it or the genetic weaknesses and predisposing of our patients. There is big gaps and people once again give cannabis this pass that it's natural and it's totally fine but there are people who have problems with it. There are addicted to it there are people who don't think as well with it and being fat soluble weird quality, not many drugs are truly fat soluble as this that it becomes part of our cellular Milieu and there is so much that is undiscussed yet that we'd have to share with everybody. I think this is one of those situations to get it right and legitimate and scientific and package it in a way physician feel comfortable with. Modalities/Methods



Online program for various training levels and certification classroom,
seminars settings or a combo of both and who is trained and to what
degree.
Cannabis providers and Cannabis specialists- to what degree do we expect people who are consulting in cannabis and having patients referred to them and how do we certify them and how do we make sure they are competent to deliver that sort of care and that care is consistent amongst all the people in the state of Oregon who are offering consultative services. Where do pharmacists fit in to this as consultants or otherwise. And the degree of training for all those groups.
Content
Getting folks up to speed on the legal issues dosage and delivery methods science and biochemistry
Education that really focuses on indications, really understanding how it's usefully and where it's useful so people feel comfortable.



A part of standardizing the training, improving research, improving tracking
methods clinically will change the qualifying conditions list. There are many
more medical conditions that cannabis can treat and people are going to rec
shops to get products to treat but they cannot qualify for and so also
somehow maybe getting the OLCC involved and really collecting the data for
consumers and the reasons why they are going to the rec shop without a
medical card purchasing product is going to be very interesting because I
wager that half or even the majority of patients that are going rec shops are
still going there for overall wellness purpose so I think again with tracking
and collecting data that we are going improve training that we are going
improve access to medicine and there is a subcommittee on diversion. Over
production in Oregon is a big deal right now. So, my question to the OLCC is
why is there a bump up canopy for Medical when we have over production.
I see an opportunity for reduced or free medicine to qualified medical
patients.
We need to hit a wider group of people to start putting bug in their ear and
that is probably one of the things this commission should talk about. How
do we get information out there to the majority of the people so they can



		· · · · · · · · · · · · · · · · · · ·
	start hearing it and we can start coming to a conclusion and people can hear	
	somethings a little bit different. We need to figure out how to get it out of	
	the little bubble that we are all seeing the same ole folks at and get it	
	outside where most people are hearing this information.	
	There are medical providers who absolutely have to know something and I	
	would consider them Emergency room physicians or Urgent physicians and	
	then second only to them primary care clinicians of whatever sort because	
	as people are using cannabis whether they're a patient or not, but if the	
	consume too much THC they run the risk of freaking out to the point where	
	they're going to urgent care, they are going to the emergency rooms or they	
	are not disclosing their use to their physicians because they don't have a	
	card they'll get labeled an addict or abuser so I do think that we might have	
	to talk about some level of mandatory training for the providers in the front	
	line who are engaging these patients so that their providing good care.	
Discussion:	Oregon Nurses Association, Boards of Naturopathic Medicine, Nursing,	Rachel Knox
Special Interest	Pharmaceutical and The Associated Professions	
Groups and		
other resource	Psychiatrists	
needs		



American Industrial Hygiene Association – occupational health
Hospice group
Hospitals – Surveying physicians at hospitals that would be interested to learn more about Cannabis
Department of Education- In highs schools, public health education and athletic programs.
Laboratory folks and agricultural folks. OSU-herbalists
Oregon Medical Association, Oregon Medical Board, Oregon Health Authority, OLCC
Budtenders – If we are developing training for dispensaries maybe we should hear the view of these folks.
Cultivators and Processors
We want to engage with them and get feedback as we are developing trainings



different	rill be doing their own survey to in avenues- Carole Yann will conne fic questions she'd like to ask OM	ct with Dr. Rachel Knox	and find	Rachel Knox/Public
Public Comment			F	Rachel Knox/Public

The Oregon Cannabis Commission

Web Address: WWW.Healthoregon.org/cannabiscommission